title: Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab.
abstract: Psoriasis is a chronic inflammatory disease with a prevalence of approximately 2-3% in the general population. The majority of diagnosed patients have plaque psoriasis, and about 20% have moderate-to-severe disease. Itolizumab, a new monoclonal antibody specific for the CD6 molecule mainly expressed on T lymphocytes, has demonstrated to inhibit in vitro ligand-induced proliferation and pro-inflammatory cytokine production. We assessed the immunological and histopathological effect of the antibody using clinical samples taken from 26 patients with moderate-to-severe psoriasis included in a clinical trial. The precursor frequency of lymphocytes activated with anti-CD2/CD3/CD28 beads, as well as the number of interferon (IFN)-γ-secreting T cells after stimulation, were measured at different time points of the study. Serum cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. Additionally, lymphocyte infiltration and epidermis hyperplasia were studied in five patients. A significant reduction in T cell proliferation capacity and number of IFN-γ-producing T cells was found in treated patients. Serum levels of interleukin-6, tumor necrosis factor and IFN-γ showed an overall trend toward reduction. No anti-idiotypic antibody response was detected. A significant reduction in the epidermis hyperplasia was observed in analyzed patients. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease.
authors.affiliation: Center of Molecular Immunology; Havana, Cuba.
authors.forename: Lazaro E
authors.initials: LE
authors.lastname: Aira
authors.affiliation: Center of Molecular Immunology; Havana, Cuba; Biotech Pharmaceutical Co. Ltd.; Beijing, China.
authors.forename: Alejandro
authors.initials: A
authors.lastname: López-Requena
authors.affiliation: National Center for Laboratory Animal Breeding; Havana, Cuba.
authors.forename: Dasha
authors.initials: D
authors.lastname: Fuentes
authors.affiliation: Center of Molecular Immunology; Havana, Cuba.
authors.forename: Liset
authors.initials: L
authors.lastname: Sánchez
authors.affiliation: Hermanos Ameijeiras Hospital; Havana, Cuba.
authors.forename: Teresita
authors.initials: T
authors.lastname: Pérez
authors.affiliation: Medical Surgical Research Center; Havana, Cuba.
authors.forename: Aleida
authors.initials: A
authors.lastname: Urquiza
authors.affiliation: Manuel Fajardo Hospital; Havana, Cuba.
authors.forename: Heber
authors.initials: H
authors.lastname: Bautista
authors.affiliation: Carlos Juan Finlay Hospital; Havana, Cuba.
authors.forename: Leopoldina
authors.initials: L
authors.lastname: Falcón
authors.affiliation: Center of Molecular Immunology; Havana, Cuba.
authors.forename: Patricia
authors.initials: P
authors.lastname: Hernández
authors.affiliation: Center of Molecular Immunology; Havana, Cuba.
authors.forename: Zaima
authors.initials: Z
authors.lastname: Mazorra
mesh_terms: D000328:Adult; D000368:Aged; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D061067:Antibodies, Monoclonal, Humanized / Q000276:immunology* / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D049109:Cell Proliferation; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology; D055815:Young Adult
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; C062279:CD6 antigen; D016207:Cytokines; D007371:Interferon-gamma; C000597346:itolizumab
keywords: CD6; anti-idiotypic antibody response; cell proliferation; epidermal hyperplasia; itolizumab; pro-inflammatory cytokines; psoriasis